Gilead Acquires CD47 Focused Forty Seven for US$4.9 B
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 3 (Table of Contents)
Published: 4 Mar-2020
DOI: 10.3833/pdr.v2020.i3.2517 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a bid to grow its immuno-oncology portfolio, Gilead Sciences has agreed to acquire Forty Seven, a clinical-stage company developing therapies targeting CD47...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS